PPT-Statin Landmark Trials Across the Spectrum of Risk: Seconda

TNT Study Design Treating to New Targets 2 5 years 10001 Patients Clinically evident CHD LDLC 130 250 mgdL following up to 8week washout and 8week openlabel

event atorvastatin primary nonfatal atorvastatin event nonfatal primary point death major events engl med 2005 001 time stroke patients

Presentation Embed Code

<iframe width="560" height="315" src="https://www.docslides.com/embed/389263" frameborder="0" allowfullscreen></iframe>

Download Presentation

Download Presentation The PPT/PDF document "Statin Landmark Trials Across the Spectr..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.